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Objective. Compared to autologous bone grafts, allogeneic bone grafts integrate slowly, which
can adversely affect clinical outcomes. Here, our goal was to understand the molecular
mechanisms underlying graft incorporation, and then test clinically feasible methods to
accelerate this process.
Methods. Wild-type and transgenic Wnt  “reporter” mice were used in a vertical ridge aug-
mentation procedure. The surgery consisted of tunneling procedure to elevate the maxillary
edentulous ridge periosteum, followed by the insertion of bone graft. Micro-computed tomo-
graphic imaging, and molecular/cellular analyses were used to follow the bone graft over
time. Sclerostin null mice, and mice carrying an activated form of -catenin were evaluated
to  understand how elevated Wnt  signaling impacted edentulous ridge height and based
on  these data, a biomimetic strategy was employed to combine bone graft particles with
a  formulation of recombinant WNT protein. Thereafter, the rate of graft incorporation was
evaluated.
Results. Tunneling activated osteoprogenitor cell proliferation from the periosteum. If graft
particles were present, then osteoprogenitor cells attached to the matrix and gave rise to
new  bone that augmented edentulous ridge height. Graft particles alone did not stimu-
late  osteoprogenitor cell proliferation. Based on the thicker edentulous ridges in mice with
amplified Wnt  signaling, a strategy was undertaken to load bone graft particles with WNT;
this  combination was sufficient to accelerate the initial step of graft incorporation.
Significance. Local delivery of a WNT  protein therapeutic has the potential to accelerate graft
incorporation, and thus shorten the time to when the graft can support a dental implant.
©  2020 The Academy of Dental Materials. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
).
∗ Corresponding author at: Stanford University, 1651 Page Mill Road, Palo Alto, CA 94304, USA.
E-mail address: jhelms@stanford.edu (J.A. Helms).
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0109-5641/© 2020 The Academy of Dental Materials. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.  Introduction
For decades, autologous bone has served as the standard of
care for the reconstruction of large bony defects [1]. Autol-
ogous bone grafts (autografts) contain osteoprogenitor cells,
a mineralized matrix scaffold, and growth factors that col-
lectively allow the graft to seamlessly integrate at the site of
transplantation [2]. Nonetheless, there are disadvantages to
autografting: first, there is persistent discomfort that accom-
panies the harvesting of bone from the iliac crest [3,4]. Second,
there is often a limited amount of autograft that can be har-
vested [5]. Third, there is the issue of osteogenic potential: the
older the patient, the less osteogenic the autograft becomes
[6]. Finally, there is the issue of resorption: despite initial gains,
over time, autografted sites undergo a significant loss in vol-
ume  [7,8].
Collectively, these disadvantages have made way for
the development of bone graft extenders (reviewed in
[9]). Their ease of use and unlimited quantities are two
major advantages, but all allogeneic bone graft exten-
ders must undergo deproteinization and decellularization to
ensure immune-compatibility [10], Since they are devoid of
stem/osteoprogenitor cells, and pro-osteogenic proteins, new
bone tends to form very slowly around allografts [11,12]. This
delayed graft incorporation is problematic and contributes to
greater variability in clinical outcomes when allografts are
used [13]. We  reasoned that if the rate of new bone formation
could be accelerated around allografts, then these materials
may effectively replace the need for autografts.
WNT  proteins are potent, pro-osteogenic factors [14–16]
that stimulate osteogenesis by activating the osteogenic tran-
scription factor Runx2 [17–19], and repressing bone-resorbing
pathways via a RANKL-dependent mechanism [20,21]. WNT
proteins, however, are lipophilic and thus aggregate in aque-
ous in vivo environments. To prevent loss of activity, our
laboratory developed a liposomal formulation of WNT3A
e.g., l-WNT3A [22–24]. The liposome interacts with the gly-
cosylated, palmitoylated modifications on WNT  proteins,
which are essential for Wnt  signaling activity [25]. Lipo-
somal packaging stabilizes the WNT  protein, extending its
half-life in vivo from minutes to multiple hours [22]. in vivo,
l-WNT3A activates osteoprogenitor cells, leading to their
accelerated differentiation into matrix-secreting osteoblasts;
consequently, we reasoned that combining this protein ther-
apeutic with a non-resorbing allogeneic bone matrix scaffold
might promote the activation of endogenous Wnt-responsive
osteoprogenitor cells at the site of grafting, which in turn
would accelerate the rate of new bone formation around the
allograft.
We  tested this possibility in a craniomaxillofacial proce-
dure where allograft materials are used to increase the vertical
dimension of an atrophied maxilla or mandible to support
the placement of an implant [26]. A vertical ridge augmenta-
tion procedure was performed in the murine edentulous ridge,
which lies between the first molar and incisors and is com-
prised of dense lamellar bone, similar to an atrophied human
maxillae or mandible [26]. This region was large enough to per-
mit  the insertion of micro-forceps to create a periosteal tunnel,
into which bone graft particles could be inserted. The fate(s)
of Wnt-responsive cells around the particles, and the effects
of l-WNT3A, could then be monitored over time.
2.  Materials  and  methods
2.1.  Animals
Experimental protocols followed ARRIVE guidelines and
were approved by the Stanford Committee on Animal
Research (#13146). Wild-type and Axin2CreERT2/+;R26mTmG/+
mice (#018867 and #007576) were purchased from Jackson Lab-
oratories. Both genders were used. All mice were between 6–8
weeks old at the initiation of the experiment.
A strain of Wnt  reporter mice (Axin2CreERT2/+;R26mTmG/+)
was employed in some experiments. In this strain, Cre expres-
sion is under the control of the Wnt  target gene, Axin2 [27].
Cre mediated recombination was induced by intraperitoneal
delivery of tamoxifen (4 mg/25 g body weight); thereafter,
Wnt-responsive cells are identifiable by expression of green
fluorescent protein (GFP). Descendants arising from the ini-
tial population of Wnt-responsive cells are also labelled with
GFP, which allowed for the unambiguous identification of
Wnt-responsive cells in the periosteum. In our experiments,
tamoxifen was delivered intraperitoneally for 3 consecutive
days; animals were sacrificed 7 days after the last injection.
DacatOt mice and Sost−/− mice were generated in the lab-
oratory of Dr. Teresita Bellido, whose protocol was approved by
the Institutional Animal Care and Use Committee of Indiana
University School of Medicine. DacatOt mice were generated
as described [28], by crossing dentin matrix acidic phosphopro-
tein 1 (DMP1)−8kb-Cre mice with Catnblox(ex3) mice in which
LoxP sites flank exon 3 that encodes for -catenin degradation.
DMP1−8kb-Cre+/− mice were crossed with Catnblox(ex3)/lox(ex3)
mice to generate Catnblox(ex3)/+ ; DMP1−8kb-Cre+/− (dacatOt
mutant mice) and Catnblox(ex3)/+ mice (dacatOt control) mice.
Sost−/− mice carried a targeted disruption of the SOST coding
region and were generated as described [28].
2.2.  l-WNT3A  formulation  and  Wnt  reporter  activity
assay
l-WNT3A was prepared as described in detail [22]. In brief,
recombinant human WNT3A protein was combined with pre-
formed DMPC:cholesterol (90:10) liposomes and incubated at
room temperature for 2 h to generate WNT-lipid nanoparticles
[22]. An identical liposomal formulation of phosphate buffered
saline e.g., l-PBS was manufactured and used as a control.
The activity of l-WNT3A used here was validated using a
cell-based potency LSL assay, in which mouse LSL cells were
stably transfected with a Wnt-responsive luciferase reporter
plasmid, pSuperTOPFlash (Addgene) containing 3 TCF/LEF
binding sites regulating expression of luciferase. When LSL
cells are exposed to l-WNT3A, the Wnt  protein binds to Friz-
zled (Fz) receptors on the surface of the LSL cells, which
initiates a cascade of Wnt-dependent intracellular events [29]
that leads to the expression of luciferase [30]. After exposure
to the Wnt  stimulus, LSL cells were incubated for an addi-
tional 18 h at 37 ◦C, 5% CO2 in 1 × DMEM (Invitrogen), 10 % FBS
(Gibco), and 1% Penicillin/Streptomycin (P/S, Mediatech). Then
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prior to quantification, cells were washed to remove exoge-
nous Wnt  and lysed with Lysis Buffer (Applied Biosystems).
Luciferin was added to the culture medium, and underwent
cleavage by luciferase; the energy released by this reaction was
in the form of light [31] that was detected by a dual light reader.
l-WNT3A potency was defined by comparing the readouts of
samples to that of a reference standard consisting of recom-
binant human WNT3A protein (StemR&D), tested at known
concentrations.
2.3.  Allograft  preparation  and  treatment  with
l-WNT3A
To allow placement in a mouse surgical site, bone matrix was
placed into a mortar and ground with a pestle into smaller
particles e.g., ∼15−200 m.  Graft particles were then soaked
in either l-WNT3A (concentration =0.3 ng/L) or l-PBS at 4
◦C for 15 min. To measure entrapment and release of active
l-WNT3A, particles were removed from their solutions and
placed onto LSL cells which were seeded at 50,000 cells/well in
a 4-well chamber slide (Thermo) and allowed to recover for 4 h.
After 18 h, cells were fixed in 4% PFA then immunostained for
luciferase expression (see immunostaining described below).
Cell nuclei were counter-stained with DAPI. Negative and pos-
itive control wells were treated with l-PBS and l-WNT3A,
respectively, at a concentration of 10 L in 100 L total culture
medium volume.
Quantification of Wnt  activity in response to l-WNT3A
delivered via bone graft particles was performed using Adobe
Photoshop and ImageJ. Three samples co-cultured with l-
WNT3A soaked bone graft were included. The first ROI was
defined as an annulus around the bone graft particle with a
width of 150 m,  while the second was defined as the annulus
around the first annulus with the same width. Total cell num-
bers were counted using particle analysis in ImageJ, while the
numbers of luciferase+ve cells were counted manually. Then
the percentage of luciferase+ve cells was calculated.
2.4.  Subperiosteal  tunneling  and  bone  graft  placement
A vertical ridge augmentation procedure was performed using
bone graft particles. Prior to the tunneling and/or grafting pro-
cedure, mice were anesthetized, and the mouth was rinsed
using povidone-iodine solution for 1 min. A full-thickness
incision was made between the first and second rugae, per-
pendicular to the maxillary bone surface. Micro-forceps were
used to reflect the periosteum towards the maxillary first
molar. Bone graft particles, either treated with l-WNT3A or
with l-PBS (as above), were gently inserted into the tunnel.
The surgical site was closed with non-absorbable single inter-
rupted sutures (Ethilon nylon suture black monofilament 8-0,
Johnson & Johnson Medical). Mice were fed provided regular
hard-food chow (#2918, Envigo) and water ad libitum. Mice
were sacrificed at timepoints indicated (see Appendix Table
1 for experimental groups, timepoints, and sample sizes).
2.5.  Micro-computed  tomography  (CT)
Samples were collected after euthanasia. The maxillae were
split sagittally with a sharp blade. Tissues were fixed in 4%
paraformaldehyde overnight at 4 ◦C. Three-dimensional CT
scanning and analyses followed published guidelines [32].
Scanning was performed using a CT data-acquisition sys-
tem (VivaCT 40, Scanco) at 10.5 m voxel size (70 kV,  115 A,
300 ms  integration time). Three-dimensional reconstruction
and volume rendering were carried out using Avizo (FEI, Hills-
boro, OR), Dataviewer (SkyScan) software and ImageJ (NIH,
Bethesda, MD) software. Bone morphometry was evaluated
using CTAn software (SkyScan, Belgium). Images were orga-
nized using Adobe Photoshop and Adobe Illustrator.
2.6.  Tissue  collection,  processing  and  histology
Following the CT imaging, samples were transferred to a
microwave oven (Ted Pella, Redding, CA), in which a circu-
lating 10 % ethylenediamine tetraacetic acid solution was
held for decalcification. After a 2-week demineralization
period, specimens were dehydrated through an ascending
ethanol series then paraffin-embedded. 8m-thick sagittal
sections were cut and collected on Superfrost-plus slides for
histology including Aniline blue, Masson’s Trichrome, Movat’s
pentachrome, and Picro-sirius red staining, which followed
published protocols [27].
2.7.  Immunostaining
Immunostaining followed published protocols [33]. In brief,
tissue sections were de-paraffinized then permeabilized
with 0.5 % TritonX-100. Antigen retrieval was performed
using Antigen Unmasking Solution (Vector Labs), follow-
ing which slides were blocked with 5% goat serum
(Vector S-1000) for 1 h at room temperature then incu-
bated with primary antibodies overnight at 4 ◦C. After
washing with PBS, slides were incubated with Cyanine5
conjugated goat anti-rabbit secondary antibody (Invitrogen,
A-10523) for 30 min, then mounted with 4′,6-diamidino-2-
phenylindole (DAPI) mounting medium (Vector Labs). Primary
antibodies used in this study include anti-luciferase anti-
body (1:1000, ab21176, Abcam), anti-PCNA (1:5000; ab18197,
Abcam), anti-Runx2 (1:1000; ab192256, Abcam), and anti-green
fluorescent protein (GFP) (1:400; 2956S, Cell Signaling Technol-
ogy).
2.8.  Alkaline  phosphatase  (ALP)  and
Tartrate-resistant  acid  phosphatase  (TRAP)  activity
To detect ALP activity, tissue sections were treated with
ALP-detection solution containing BCIP (5-bromo-4-chloro-3-
indolyl phosphate; Roche, #11383221001) and NBT (nitro blue
tetrazolium chloride; Roche, #11383213001) according to the
manufacturer’s instructions. TRAP activity was observed using
a leukocyte acid phosphatase staining kit (catalog #386A-1 KT,
Sigma-Aldrich). Tissue sections were processed according to
the manufacturer’s instructions.
2.9.  Histomorphometric  analyses
Histomorphometric measurements were performed using
Adobe Photoshop. A minimum of 3 grafted sites/time point
were analyzed for each treatment group. For each site, a min-
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imum of three aniline blue-stained sagittal tissue sections,
which included the mesial labial root as a landmark, were
used to quantify maxillary bone thickness, and augmented
thickness. Each tissue section was photographed using a
Leica digital image  system at 20x magnification. To obtain
the augmented height, the region of newly formed bone was
selected manually in Photoshop, then the area and width of
the selected pixels was recorded using the measurement log.
The average augmented thickness was calculated by dividing
the area selected by its width. In addition, the area occupied
by the bone graft particles was also manually selected and
recorded. From these measurements, the composition e.g.,
particles versus new bone of the total augmented region was
determined.
To evaluate Runx2 expression in response to l-PBS versus
l-WNT3A treatment, 3 graft sites from each treatment group
were analyzed. From each site, at least 3 sagittal tissue sec-
tions were analyzed. The lasso tool in Adobe Photoshop
was used to select a region of interest (ROI), which was the
“pocket” area generated by the tunneling procedure. Within
this ROI, the space occupied by bone graft particles was
excluded. The number of Runx2+ve cells and the total num-
ber of the other cells (identified by DAPI) were then counted,
and the ratio of Runx2+ve to total cells was then calcu-
lated.
To visualize collagen organization, 3 graft sites were
selected from the l-PBS group and 3 graft sites from the l-
WNT3A group, then 3 sagittal tissue sections from each of the
specimens were analyzed. Picro-sirius red stained slides were
viewed under polarized light using a Leica digital image  sys-
tem at 20x magnification. The same “pocket” ROI was selected,
as described above. With the color analysis tool in Photoshop,
the number of orange/red pixels, corresponding to mature col-
lagen fibers, were selected using a uniform color range and
counted, and the same was done for green pixels, which cor-
responded to immature collagen fibers. Then, the total pixels
within the same ROI was determined. Mature/immature col-
lagen fibers were expressed as a percentage of their respective
pixels/total pixels in the ROI.
2.10.  Statistical  analysis
Results were presented as mean ± standard deviation. All
statistical analyses were performed using the Prism 7.0
(GraphPad Software). Comparisons of immunopositive cell
percentage and collagen organization were analyzed using
the two-tailed Student’s T-test. Comparisons of augmented
maxillary height with non-treated bone grafts were based
on a one-way ANOVA followed by Turkey’s post-hoc testing.
While, comparisons of augmented maxillary height with l-
WNT3A/L-PBS treated bone graft were performed based on
a two-way ANOVA with Geisser-Greenhouse correction, fol-
lowed by Turkey’s post-hoc testing for multiple comparisons.
Significance was attained at p < 0.05 (*), p < 0.01(**), and p <
0.001(***). An online tool, designed for calculating the mini-
mum sample size for adequate study power, was employed:
https://clincalc.com/stats/SampleSize.aspx.
3.  Results
3.1.  Establishing  a  rodent  model  of  vertical  ridge
augmentation  via  tunneling  and  bone  grafting  procedures
On atrophic maxillae and mandibles, vertical ridge augmen-
tation is performed when there is insufficient bone volume
to support an implant. To mimic  this clinical scenario, the
rodent edentulous ridge was selected. Its thin, lamellar, dense
bone (Fig. 1A) resembles the type of bone clinicians usually
encounter when performing vertical ridge augmentation [26].
Bone grafting was accomplished using bovine mineralized
matrix particles (see Methods). In most cases (14/16) the bone
graft remained on the crest of the edentulous ridge (arrows,
Fig. 1B), stabilized there by a soft tissue envelope produced
via a subperiosteal tunneling procedure. In cases where the
graft shifted from its original position (N = 2), samples were
excluded from further analyses.
We inspected the clinical response to vertical ridge
augmentation, separating the tunneling component of the
surgery from the grafting procedure. Intact tissues served
as controls (Supplemental Fig. 2A). The tunneling procedure
resulted in an irregular border of the maxillary bone (dotted
white line, Fig. 1C compared with controls, Supplemental Fig.
2A). In cases where bone graft had been inserted into the soft
tissue envelope, graft particles (dotted black lines, Fig. 1D) were
observed next to the irregular maxillary bone and in some
instances, new woven bone was detected near the particles
(green arrowheads, Fig. 1E). Over time, bone graft particles
near to the maxillary bone became embedded in new bone
matrix (green arrowheads, Fig. 1F,G).
Using picrosirius red staining and polarized light, new
bone matrix was easily distinguished from pre-existing max-
illary bone by virtue of its immature collagen organization
(Fig. 1H). Quantitative CT imaging on post-surgery day (PSD)
28 illustrated the extent to which the bone graft was fully
incorporated into new bone (arrows, Fig. 1I). Vertical maxillary
bone height was quantified as a function of time post-grafting:
between PSD0 and 9, there was minimal change in the thick-
ness of the maxillary edentulous ridge (Fig. 1J). By PSD14, the
grafted ridge was ∼20 % thicker and by PSD28, the ridge height
had more  than doubled, i.e. increased by 141 % of its origi-
nal thickness (Fig. 1J). Some of this vertical gain in height was
directly due to the volume of the graft particles, and some
was due to new bone formation; we analyzed the ratio and
found that of the augmented bone volume, nearly 60 % was
due exclusively to new bone formation (Fig. 1K). The remain-
ing 41 % of augmented bone volume was due to the particles
themselves.
Our next analyses focused on pinpointing the source of this
new bone. One early clue came from an examination of the
intact maxillary periosteum (Fig. 1L). Compared to the nasal
surface (denoted n po), the periosteum on the oral surface
(o po) was noticeably thicker and densely cellular (Fig. 1L,M).
Periostea are niches for osteoprogenitor cells [34,35], which
suggested that the new bone that gradually enveloped the
graft particles might arise from this source. We  therefore
focused on how oral periosteum responded to tunneling and
grafting procedures.
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Fig. 1 – A rodent model of vertical ridge augmentation with bone graft.
CT scanning and 3D reconstruction of the maxillary edentulous ridge in the (A) intact state and (B) 6 days following
placement of a bone graft between the maxillary bone and the periosteum. Aniline blue staining of representative tissue
sections through the maxillary edentulous ridge on PSD6 following (C) a tunneling procedure; and (D) a tunneling procedure
plus bone grafting; dotted white line indicates the border of the maxillary bone; dashed black lines indicate borders of the
graft particles. A tunneling procedure plus bone grafting, on (E) PSD9, (F) PSD14, and (G) PSD28; green arrow heads indicate
the newly  formed bone. (H) Picrosirius red staining of the near-adjacent tissue section of G; dashed white lines indicate
borders of the bone graft particles. (I) CT scanning and 3D reconstruction of the maxillary edentulous ridge 28 days
following the grafting. (J) Histomorphometric quantification of the maxillary edentulous ridge basal bone height and
augmented bone height. (K) Pie chart showing the fraction of bone graft in total augmented area in grafted mice 28 days
following the grafting. (L) Masson’s trichrome staining of a representative tissue section through the intact maxillary
edentulous ridge illustrating the maxillary periostea. (M)  DAPI staining to detect cell nuclei. The dotted white lines
demarcate the edges of the maxillary bone. Abbreviations: mxM1,  maxillary first molar; Cor, coronal plane; Tra, transaxial
plane; Sag, sagittal plane; su, suture; mx,  maxilla; o po, oral periosteum; n po, nasal periosteum. Scale bars: 50 m if not
indicated.
3.2.  Tunneling  activates  osteoprogenitor  proliferation
in the  periosteum
The periosteum was noticeably thicker following the tunnel-
ing procedure (compare Fig. 2A with B and C). The thicker
periosteum was a site of active mineralization (compare
Fig. 2D with E and F). This expansion in ALP activity caused by
tunneling correlated with increased mitotic activity, as shown
by PCNA immunostaining (compare Fig. 2G with H and I).
These proliferating cells were osteoprogenitors, as shown by
the distribution of Runx2+ve cells (compare Fig. 2J with K and
L).
The presence of the bone graft particles had a dramatic
effect on the distribution of proliferating osteoprogenitor cells:
rather than remaining close to the native bone surface, if bone
graft was used, PCNA+ve, Runx2+ve cells encircled the parti-
cles (compare Fig. 2H with I and K with L). Clearly then, the
presence of a mineralized matrix was sufficient to cause the
migration of osteoprogenitor cells away from their site of ori-
gin. We also found that PCNA+ve, Runx2+ve osteoprogenitor
cells were only increased in number if the periosteum was
elevated off the bone surface: creating a connective tissue tun-
nel that left the periosteum attached to the bone did not lead
to osteoprogenitor cell proliferation (not shown). Even creat-
ing a connective tissue tunnel and introducing graft particles
was not sufficient to activate osteoprogenitor cell proliferation
(Supplemental Fig. 3). Collectively, these data demonstrated
that elevating the periosteum led to the proliferation of osteo-
progenitor cells and if a graft were present then these new
osteoprogenitor cells enveloped and attached the particles.
3.3.  Enhanced  Wnt  signaling  correlates  with  bone
accrual
What signals were responsible for triggering the prolifera-
tion of osteoprogenitor cells in the injured periosteum? In
the intact state, the periosteum is Wnt-responsive (Fig. 3A,B)
and at least some of these Wnt-responsive cells co-stain for
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Fig. 2 – A tunneling procedure activates osteoprogenitor cell proliferation.
Masson trichrome staining of representative tissue sections through the maxillary edentulous ridge (A) in the intact state
and on PSD6 following (B) a tunneling procedure and (C) a tunneling procedure plus bone grafting. ALP activity in the (D)
intact periosteum, versus ALP activity 6 days following (E) a minimally invasive tunnel procedure and (F) a tunneling and
bone grafting. In a near-adjacent tissue section, PCNA immunostaining in the (G) intact periosteum, versus on PSD6
following (H) a tunneling procedure and (I) a tunneling procedure plus bone grafting. Runx2 immunostaining in the (J) intact
periosteum, versus on PSD6 following (K) a tunneling procedure and (L) a tunneling procedure plus bone grafting.
Abbreviations and dotted and dashed lines: as in Fig. 1. Scale bars: 50 m.
Runx2 (Fig. 3C). We reasoned that if Wnt  signaling was critical
for the proliferation of osteoprogenitor cells and bone accrual,
then genetic models of elevated Wnt  signaling should mani-
fest as having thicker periostea and thicker edentulous ridges.
We first evaluated mice carrying null mutations in the Wnt
inhibitor, Sclerostin, which have elevated endogenous Wnt
signaling [36]. Compared to wild-type mice (Fig. 3D-F), Sost−/−
mice had a significantly thicker edentulous ridge (Fig. 3G-I;
quantified in M)  but not a noticeably thicker periosteum. We
therefore evaluated a second genetic model of amplified Wnt
signaling, e.g., dacatOt mice, which carry an activated form
of -catenin [37]. DacatOt mice not only had a significantly
thicker edentulous ridge (Fig. 3J,K; quantified in M), but also a
noticeably thicker periosteum (Fig. 3L).
3.4.  Use  of  a  WNT-bioactivated  graft  accelerated  bone
accrual
Deletion of SOST and over-expression of activated -catenin
were genetic strategies to increase Wnt  signaling; we under-
took a clinically feasible method of increasing Wnt  signaling
around bone graft particles. WNT  liposomes are ∼80 nm in
diameter, and the average pore size in the bone graft was ∼1
m; therefore, we incubated the particles in l-WNT3A, the-
orizing that at least some of the protein therapeutic might
become entrapped in the pores and then leach out over time.
To test entrapment and release, we  used an LSL cell assay. LSL
cells are engineered to express luciferase in response to a Wnt
stimulus [22]. The specificity of the luciferase response, and
the activity of l-WNT3A, were both demonstrated (Fig. 4A,B).
Bone graft particles were then soaked in l-PBS or l-WNT3A;
after 15 min, the treated particles were transferred onto LSL
cells. LSL cells incubated with l-PBS treated bone graft parti-
cles did not express luciferase (Fig. 4C). In contrast, l-WNT3A
treated bone particles were surrounded by a halo of luciferase-
expressing cells (Fig. 4D). The luciferase-expressing cells were
contained within a 150 m zone surrounding the particles
(Fig. 4E). These data demonstrated that bone graft particles
could entrap and then release active l-WNT3A.
We tested the effects of l-WNT3A-bioactivated bone graft
particles in vivo. l-PBS and l-WNT3A treated bone graft parti-
cles were prepared and placed onto the edentulous ridge. Six
d e n t a l m a t e r i a l s 3 6 ( 2 0 2 0 ) 1303–1313 1309
days later, significantly more  Runx2+ve osteoprogenitor cells
were detected around WNT-bioactivated particles (compare
Fig. 4F,G; quantified in H). Collagen matrix appeared to more
mature around the WNT-bioactivated particles, as shown by
Picrosirius red staining (Fig. 4I,J; quantified in K).
By PSD9, more  bone surrounded the WNT-bioactivated par-
ticles (Fig. 4L,M; quantified in P) but by PSD14 the amount of
new bone appeared to be equivalent between the experimen-
tal groups (Fig. 4N,O; quantified in P). Collectively, these data
demonstrated a significant but transient acceleration in new
bone formation around WNT-bioactivated bone graft particles.
4.  Discussion
4.1.  A  rate-limiting  step  in  graft  incorporation  is
proliferating  osteoprogenitor  cell  recruitment
Despite obvious advantages, the use of bone allograft lags far
behind autografting for the reconstruction of large skeletal
defects (reviewed in [9]). Autografts contain osteoprogenitor
cells, a mineralized matrix scaffold, and growth factors that
collectively allow the graft to seamlessly integrate at the site
of transplantation. Allografts, on the other hand, are pre-
dominantly comprised of the mineralized matrix fraction of
bone that has undergone deproteinization and decellular-
ization to ensure immune-compatibility [38]. Compared to
autologous bone grafts, allografts incorporate slowly. This is
not an issue of immune compatibility; rather, creeping graft
incorporation is a direct result of the deproteination and decel-
lularization steps that remove both osteoprogenitor cells and
pro-osteogenic proteins.
The ingrowth of osteoprogenitor cells onto the allo-
graft scaffold is a passive, and thus slow, process [39,40],
and has been implicated as a contributing factor in the
greater variability in clinical outcomes that are observed
when allografts are used [41]. Since a graft must be biolog-
ically incorporated before it can be used for load-bearing
purposes e.g., to support a dental implant, methods to
Fig. 3 – Upregulated Wnt  signaling resulted in high bone mass.
(A) Pentachrome staining illustrating the intact maxillary periosteum of oral surface. (B) GFP immunostaining of the
near-adjacent tissue section of A indicating the distribution of Wnt-responsive cells. (C) Merged GFP and Runx2 co-staining
of B. (D) Representative sagittal section of CT scanning of the maxillary edentulous ridge and (E, F) pentachrome staining
of a representative tissue section through the same site in wild-type control mice. Representative (G) CT section and (H, I)
pentachrome staining of a tissue section in Sost−/− mice. Representative (J) CT section and (K, L) pentachrome staining of a
tissue section in daßcatOt mice. (M)  Quantification of the maxillary edentulous ridge basal bone height. (O) ALP activity and
(P) Runx2 immunostaining of the near-adjacent tissue section of L; (Q) ALP activity and (R) Runx2 immunostaining of the
near-adjacent tissue section of M.  Black double-headed arrows indicate the maxillary edentulous ridge basal bone height of
wild-type mice, while green arrows indicate the increased height. Abbreviations, dotted lines: as in Fig. 1. Scale bars: 50 m
if not indicated.
1310  d e n t a l m a t e r i a l s 3 6 ( 2 0 2 0 ) 1303–1313
accelerate graft incorporation have considerable clinical util-
ity.
We  gained critical insights into the problem of slow
allograft incorporation: in a vertical ridge augmentation pro-
cedure (Fig. 1), we  found that graft incorporation was related
to the recruitment and proliferation of Wnt-responsive osteo-
progenitors from the adjacent periosteum (Figs. 2,3). While
bone graft particles supported the attachment of osteoprogen-
itor cells, they did not stimulate either their recruitment from
the periosteum or enhance their proliferation (Fig. 2). Even if
particles were present but the periosteum remained intact,
few if any proliferating osteoprogenitor cells were detected
(Supplemental Fig. 3). Clearly then, methods to increase the
number and/or distribution of these proliferating progeni-
tor cells around bone graft particles represented a rationale
strategy to improve the rate of graft incorporation. Our data
demonstrate that at least the initial rate of graft incorporation
was accelerated in response to l-WNT3A (Fig. 4).
4.2.  Bioactivating  a  bone  graft  with  WNT
Wnt  proteins rank amongst the most potent pro-osteogenic
signals [42–44], which has directly led to the development
of Wnt  pathway activators for purposes of increasing bone
mass [45] and accelerating bone repair [46]. For purposes of
accelerating graft incorporation, however, systemic delivery
of drugs such as romosozumab, an anti-Sclerostin antibody
[47], is contraindicated because long-term use actually sup-
presses osteoprogenitor cell proliferation [48]. Therefore, we
looked for methods of locally delivering WNT  protein to sites
requiring bone reconstruction.
Based on the size of l-WNT3A [22] and the average pore size
in bovine bone graft [49], the entrapment and release of active
l-WNT3A from bone graft particles (Fig. 4) probably occurred
by passive diffusion. It is also likely that diffusion accounted
for the transient impact that l-WNT3A had on graft incorpora-
tion and new bone formation (Fig. 4). Consequently, methods
Fig. 4 – WNT3A accelerates the onset of new bone formation.
LSL cells, identified by DAPI staining, were  interrogated using IHC for luciferase expression following treatment with (A)
l-PBS or (B) l-WNT3A. LSL cells were  treated with bone graft particles soaked in (C) l-PBS or (D) l-WNT3A. (E) Quantification
of Wnt  activity in response to l-WNT3A delivered via bone graft particles. IHC localization of Runx2 (red signal) and DAPI
(blue signal) on representative tissue sections through the maxillary edentulous ridge on PSD6 following a transplantation
of graft in combination with a (F) l-PBS or (G) l-WNT3A. (H) Quantification of the percentage of Runx2+ve cells/total cells in a
ROI, centered on the graft particles. Picrosirius red staining showing collagen fiber organization around graft particles
treated with (I) l-PBS or (J) l-WNT3A. (K) Quantification of green pixels (corresponding to immature collagen fibers) and
red/yellow pixels (corresponding to mature fibers) in the total area around the graft particles (see Methods). Pentachrome
staining showing the maxillary edentulous ridge on PSD9 following (L) l-PBS- or (M)  l-WNT3A-combined grafting.
Pentachrome staining showing the maxillary edentulous ridge on PSD14 following (N) l-PBS- or (O) l-WNT3A-combined
grafting. (P) Histomorphometric quantification of the augmented bone height in l-PBS and l-WNT3A groups. Abbreviations,
dotted lines and dashed lines: as in Fig. 1. Scale bars: 50 m.
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to improve l-WNT3A entrapment efficiency and to allow sus-
tained, localized release kinetics are ongoing.
Physical encapsulation of a growth factor into a scaffold
is one standard approach but this method of incorporation
is inefficient and not well-suited to allogeneic bone prod-
ucts that do not undergo a gelation or solidification step.
Another commonly used strategy is immobilization, but accu-
mulating evidence shows that many  growth factors lose their
biological activity as a result [50]. When biomolecules do not
adsorb to a substrate surface, then covalent immobilization
of a growth factor to a material may improve release kinet-
ics. Chemically attaching the growth factor controls an initial
burst release because desorption is influenced by enzymatic or
hydrolytic cleavage of the chemical bond, but such methods
must also ensure that growth factor activity is not compro-
mised (reviewed in [51]).
4.3.  Vertical  ridge  augmentation  with  bone  graft
substitutes:  room  for  improvement?
Within the first year following tooth extraction, up to 25 % of
bone volume is lost [52]; volumetric changes continue for up to
5 years, leading to significant aesthetic and restorative chal-
lenges [53]. The characteristic thin, dense edentulous ridge
seen in edentulous patients is replicated in part by the murine
edentulous ridge (Fig. 1). This anatomical site in mice, how-
ever, has never supported a tooth. We compared histologic
features of the human edentulous ridge with that observed
in the mouse model. In both, the edentulous portion of the
jawbone is considerably thinner than the tooth-bearing area
(Fig. 3 and see [54]), and in both the periosteum overlying
the edentulous site is osteogenic, with defects evident in the
cortical bone structure (Fig. 1A,B and see [55]). In addition,
both exhibit a pattern of lamellar bone with minimal marrow
spaces (Fig. 1 and see [54]). Therefore, the murine edentu-
lous ridge adequately replicates the edentulous condition in
patients.
In our mouse model, the gain in vertical ridge augmenta-
tion with bone graft particles was extreme, in that the height
was more  than doubled (Fig. 1). In most clinical studies, an
increase in human ridge height of ∼19−25% (i.e. 3.85–5.14 mm)
can be expected [56]. Clearly then, this rodent model repre-
sented a robust regenerative situation compared to the clinical
situation. Since anatomical and histologic appearance of the
human and mouse edentulous ridge appeared similar, the
next most obvious difference between the two  was their age:
young adult mice were employed in our study whereas most
patients undergoing vertical ridge augmentation are ∼50 years
of age [57].
While it is formally possible that rodents are not a good
model in which to evaluate methods to improve vertical ridge
augmentation, the phenotype of the Sost−/− mutant mouse
argues against this. As we  showed, mice with null mutations
in SOST develop significantly thicker edentulous ridges (Fig. 3);
so, too, to humans carrying null mutations in SOST. Patients
with van Buchem disease and sclerosteosis develop unusually
thick, dense bone, which is especially pronounced in the jaw-
bones [58,59]. Consequently, we  look to better understand why
in a murine model the vertical ridge augmentation was partic-
ularly successful, in hopes of improving outcomes in patients
undergoing the same type of procedure.
4.4.  Limitations  of  the  study
The small size of the animal model necessitated that bone
graft particles be morselized prior to their introduction into
the tunnel. While some commercial vendors claim that at least
some of the efficacy of their bone graft materials is related to
particle size [60], we  found that the morselized particles were
effective at supporting osteoprogenitor cell attachment and
new bone formation (Figs. 1,2). Particle size does not appear
to influence the rate of new bone formation [61–63]; thus, this
may not actually constitute a limitation of the current study.
5.  Conclusions
Allogeneic bone grafts exploit an endogenous repair response
(Fig. 2) but absent the recruitment and proliferation of osteo-
progenitor cells from nearby periostea, they are ineffective
(Supplemental Fig. 3). If a bioactivated allograft could trig-
ger both the recruitment and proliferation of osteoprogenitor
cells, then this would address a key deficit in allograft incor-
poration.
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